|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The fusion oncogene, promyelocytic leukemia (PML)-retinoic acid receptor-α (RARα), is crucial for acute promyelocytic leukemia (APL) pathogenesis.
|
31654721 |
2020 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The promyelocytic leukemia (PML)-retinoic acid receptor α (RARA) fusion is hypothesized to serve a vital role in the pathogenesis of acute promyelocytic leukemia (APL), which results from a reciprocal translocation between chromosomes 15 and 17, t(15;17)(q24;q21).
|
30680014 |
2019 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is commonly characterized by the fusion of retinoic acid receptor alpha (RARA) with promyelocytic leukemia (PML).
|
31447564 |
2019 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The hallmark reciprocal chromosomal translocation t(15;17) involving fusion between the retinoic acid receptor (RARα) gene and promyelocytic leukemia (PML) gene is a characteristic feature in APL which consequently results in the emergence of PML-RARα chimeric gene.
|
29700805 |
2019 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
To understand the relationship between PML/RARα and the oncogene in the development of APL, we investigate the regulation mechanism of PML/RARα to MYB proto-oncogene and the role of this regulation on the proliferation and differentiation of APL cells.
|
30335887 |
2018 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
This interaction was disrupted by the PML-RARA t(15;17) mutation, which stems from chromosomal translocation between DNA encoding the C-terminal domain of PML and the retinoic acid receptor alpha (RARA) gene.
|
29735542 |
2018 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is characterized by the presence of the promyelocytic leukemia (PML)-retinoic acid receptor-α (RAR-α) fusion protein.
|
29344139 |
2017 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expression of the leukemia protein PML/RARα in hematopoietic progenitors displaces PML from telomeres and induces telomere shortening in the bone marrow of pre-leukemic mice.
|
26119943 |
2016 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Results of fluorescence in situ hybridization, conventional cytogenetics, reverse transcription-polymerase chain reaction (RT-PCR), and oligonucleotide microarray for PML-RARA and common APL variant translocations were negative.
|
25583766 |
2015 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this project was to validate earlier time frames for the Abbott Molecular Vysis LSI promyelocytic leukemia (PML)/ retinoic acid receptor alpha (RARA) fluorescence in situ hybridization (FISH) probe (ASR 6-16 h).
|
25639817 |
2015 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eight patients were found to harbor both PML and RARA mutations over the course of the disease.
|
26294332 |
2015 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The tumor suppressor promyelocytic leukemia (PML) was first identified as a component of PML-RARα fusion protein, one of the initiating cytogenetic abnormalities in acute promyelocytic leukemia.
|
24488785 |
2014 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
ATO enhances the conjugation of small ubiquitin-like modifiers to PML-RARα, followed by ubiquitination and degradation, relieving the genes associated with granulocytic differentiation from suppressive restraint by the oncoprotein.
|
25319615 |
2014 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inorganic arsenite (iAs(3+)) is a two-edged sword. iAs(3+) is a well-known human carcinogen; nevertheless, it has been used as a therapeutic drug for acute promyelocytic leukemia (APL), which is caused by a fusion protein comprising retinoic acid receptor-α and promyelocytic leukemia (PML).
|
24135626 |
2013 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene.
|
23208507 |
2013 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study showed that GINS2 interacted with PML-C (a structural domain of PML, which is a cutting product of PML-RARα) as demonstrated by yeast two-hybrid assay and co-immunoprecipitation, and PML (NLS-) also interacted with GINS2 by co-immunoprecipitation.
|
23589040 |
2013 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
These data emphasize the benefit of using complementary molecular methods including tCGH for detecting cryptic and variant PML-RARA translocations in unusual cases of APL.
|
23370423 |
2013 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
PML/RARα and PLZF/RARα were analyzed for the ability to form high-molecular-weight complexes, the protein stability and the potential to induce a leukemic phenotype in the presence of the interfering peptides.
|
23152790 |
2012 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
A dual color dual fusion PML-RARA FISH probe set identified a small, extra PML signal in a chromosome other than 15 or 17.
|
22982005 |
2012 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of drugs such as all-trans retinoic acid (ATRA) that promote progenitor differentiation by directly inhibiting the PML-RARα fusion protein has changed the treatment paradigm for APL and markedly improved patient survival.
|
21790894 |
2011 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Translocation breakpoints are located within the promyelocytic leukemia (PML) locus on chromosome 15 and the retinoic acid receptor alpha (RARA) locus on chromosome 17.
|
21115433 |
2010 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
We found that both all-trans retinoic acid and arsenic trioxide induce autophagy via the mammalian target of rapamycin pathway in APL cells and that autophagic degradation contributes significantly both to the basal turnover as well as the therapy-induced proteolysis of PML/RARA.
|
20574048 |
2010 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecularly, the disease is characterized by a fusion protein, promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha that results from a balanced reciprocal translocation between the PML gene on chromosome 15 and the RAR-alpha (RARA) gene on chromosome 17.
|
19840521 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of all-trans-retinoic acid (ATRA) and arsenic trioxide, both of which induce degradation of the progressive multifocal leukoencephalopathy/retinoic acid receptor alpha oncoprotein, in combination with chemotherapy is currently the accepted treatment of APL, presenting a potential paradigm for differentiation therapy in clinical oncology.
|
19468269 |
2009 |
|
Leukoencephalopathy, Progressive Multifocal
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report three of 40 diagnosed APL cases that showed morphological, cytochemical, and immunophenotypic features of hypergranular APL, but did not show a PML/RARalpha fusion signal or any of its variants, on FISH.
|
19224461 |
2009 |